{"id":136525,"date":"2025-03-18T16:54:49","date_gmt":"2025-03-18T20:54:49","guid":{"rendered":"https:\/\/wfh.org\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/"},"modified":"2025-03-26T10:07:17","modified_gmt":"2025-03-26T14:07:17","slug":"takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate","status":"publish","type":"post","link":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/","title":{"rendered":"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"136525\" class=\"elementor elementor-136525 elementor-136506\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-55a6412 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"55a6412\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cf8dfc7\" data-id=\"cf8dfc7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2ad981a elementor-widget elementor-widget-text-editor\" data-id=\"2ad981a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Takeda inform\u00f3 a la Federaci\u00f3n Mundial de Hemofilia (FMH) que esta decisi\u00f3n se tom\u00f3 debido al hecho de que las personas con trastornos de la coagulaci\u00f3n (PCTC) est\u00e1n haciendo la transici\u00f3n a terapias alternas, entre ellas otras que forman parte de los propios productos hematol\u00f3gicos de Takeda. Asimismo, la compa\u00f1\u00eda enfatiz\u00f3 que la descontinuaci\u00f3n no es por motivos de calidad o seguridad, dado que ambos productos siguen siendo eficaces y cumplen las normas reglamentarias.<\/p>\n<p>La FMH est\u00e1 consciente de que el cambio a otros productos puede resultar problem\u00e1tico. Takeda inform\u00f3 que se est\u00e1 comunicando de manera proactiva con proveedores de atenci\u00f3n m\u00e9dica (PAM) y organizaciones nacionales miembros (ONM) de la FMH en los pa\u00edses afectados a fin de apoyar la transici\u00f3n. La empresa continuar\u00e1 abasteciendo los productos a pacientes que los utilicen actualmente hasta agotar existencias o hasta su expiraci\u00f3n a mediados del 2026, con oportunidad precisa, dependiendo de la demanda y de la potencia del producto. Las terapias alternas deber\u00edan poder cubrir la demanda de HEMOFIL M y RECOMBINATE, y esperamos que los miembros de nuestra comunidad podr\u00e1n efectuar el cambio a dichas terapias alternas a la mayor brevedad posible.<\/p>\n<p>Se anima a las ONM que deseen obtener m\u00e1s informaci\u00f3n \u2013o que necesiten mayor apoyo para la transici\u00f3n de HEMOFIL M y RECOMBINATE a otros productos\u2013 a comunicarse con su gerente regional de la FMH. Las PCTC que tengan preocupaciones a este respecto deber\u00edan comunicarse con su ONM.<\/p>\n<p>Para obtener m\u00e1s informaci\u00f3n lea el texto completo (en ingl\u00e9s) de la carta de Takeda <a href=\"https:\/\/wfh.org\/wp-content\/uploads\/2025\/03\/Takeda-HEMOFIL-M-and-RECOMBINATE-18-March-2025-V3.pdf\" target=\"_blank\" rel=\"noopener\">aqu\u00ed<\/a>.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Takeda anunci\u00f3 la descontinuaci\u00f3n a escala mundial de sus tratamientos para la hemofilia A, HEMOFIL\u00ae M [factor antihemof\u00edlico (humano), m\u00e9todo M, monoclonal, purificado] y RECOMBINATE (factor de coagulaci\u00f3n VIII recombinante, octocog alfa). <\/p>\n","protected":false},"author":13,"featured_media":30516,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[121],"tags":[],"search-category":[85],"class_list":["post-136525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-declaraciones-y-notificaciones-de-la-fmh","search-category-article"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE | FMH - Federaci\u00f3n Mundial de Hemofilia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE\" \/>\n<meta property=\"og:description\" content=\"Takeda anunci\u00f3 la descontinuaci\u00f3n a escala mundial de sus tratamientos para la hemofilia A, HEMOFIL\u00ae M [factor antihemof\u00edlico (humano), m\u00e9todo M, monoclonal, purificado] y RECOMBINATE (factor de coagulaci\u00f3n VIII recombinante, octocog alfa).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\" \/>\n<meta property=\"og:site_name\" content=\"FMH - Federaci\u00f3n Mundial de Hemofilia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/wfhemophilia\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T20:54:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T14:07:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2501\" \/>\n\t<meta property=\"og:image:height\" content=\"1459\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mitch Semienchuk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mitch Semienchuk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\"},\"author\":{\"name\":\"Mitch Semienchuk\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/person\/4aea5b13c1966452a640eef39423925b\"},\"headline\":\"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE\",\"datePublished\":\"2025-03-18T20:54:49+00:00\",\"dateModified\":\"2025-03-26T14:07:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\"},\"wordCount\":289,\"publisher\":{\"@id\":\"https:\/\/wfh.org\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png\",\"articleSection\":[\"Declaraciones y notificaciones de la FMH\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\",\"url\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\",\"name\":\"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE | FMH - Federaci\u00f3n Mundial de Hemofilia\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png\",\"datePublished\":\"2025-03-18T20:54:49+00:00\",\"dateModified\":\"2025-03-26T14:07:17+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png\",\"width\":2501,\"height\":1459,\"caption\":\"lgoo\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wfh.org\/es\/#website\",\"url\":\"https:\/\/wfh.org\/es\/\",\"name\":\"FMH - Federaci\u00f3n Mundial de Hemofilia\",\"description\":\"WFH - World Federation of Hemophilia\",\"publisher\":{\"@id\":\"https:\/\/wfh.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wfh.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/wfh.org\/es\/#organization\",\"name\":\"World Federation of Hemophilia\",\"url\":\"https:\/\/wfh.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"width\":210,\"height\":63,\"caption\":\"World Federation of Hemophilia\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/wfhemophilia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/wfh.org\/es\/#\/schema\/person\/4aea5b13c1966452a640eef39423925b\",\"name\":\"Mitch Semienchuk\",\"sameAs\":[\"analytics\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE | FMH - Federaci\u00f3n Mundial de Hemofilia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/","og_locale":"es_ES","og_type":"article","og_title":"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE","og_description":"Takeda anunci\u00f3 la descontinuaci\u00f3n a escala mundial de sus tratamientos para la hemofilia A, HEMOFIL\u00ae M [factor antihemof\u00edlico (humano), m\u00e9todo M, monoclonal, purificado] y RECOMBINATE (factor de coagulaci\u00f3n VIII recombinante, octocog alfa).","og_url":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/","og_site_name":"FMH - Federaci\u00f3n Mundial de Hemofilia","article_publisher":"https:\/\/www.facebook.com\/wfhemophilia\/","article_published_time":"2025-03-18T20:54:49+00:00","article_modified_time":"2025-03-26T14:07:17+00:00","og_image":[{"width":2501,"height":1459,"url":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png","type":"image\/png"}],"author":"Mitch Semienchuk","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Mitch Semienchuk","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#article","isPartOf":{"@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/"},"author":{"name":"Mitch Semienchuk","@id":"https:\/\/wfh.org\/es\/#\/schema\/person\/4aea5b13c1966452a640eef39423925b"},"headline":"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE","datePublished":"2025-03-18T20:54:49+00:00","dateModified":"2025-03-26T14:07:17+00:00","mainEntityOfPage":{"@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/"},"wordCount":289,"publisher":{"@id":"https:\/\/wfh.org\/es\/#organization"},"image":{"@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png","articleSection":["Declaraciones y notificaciones de la FMH"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/","url":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/","name":"Takeda descontinuar\u00e1 los f\u00e1rmacos para la hemofilia HEMOFIL M y RECOMBINATE | FMH - Federaci\u00f3n Mundial de Hemofilia","isPartOf":{"@id":"https:\/\/wfh.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage"},"image":{"@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png","datePublished":"2025-03-18T20:54:49+00:00","dateModified":"2025-03-26T14:07:17+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/wfh.org\/es\/article\/takeda-descontinuara-los-farmacos-para-la-hemofilia-hemofil-m-y-recombinate\/#primaryimage","url":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-SP.png","width":2501,"height":1459,"caption":"lgoo"},{"@type":"WebSite","@id":"https:\/\/wfh.org\/es\/#website","url":"https:\/\/wfh.org\/es\/","name":"FMH - Federaci\u00f3n Mundial de Hemofilia","description":"WFH - World Federation of Hemophilia","publisher":{"@id":"https:\/\/wfh.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wfh.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/wfh.org\/es\/#organization","name":"World Federation of Hemophilia","url":"https:\/\/wfh.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","width":210,"height":63,"caption":"World Federation of Hemophilia"},"image":{"@id":"https:\/\/wfh.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/wfhemophilia\/"]},{"@type":"Person","@id":"https:\/\/wfh.org\/es\/#\/schema\/person\/4aea5b13c1966452a640eef39423925b","name":"Mitch Semienchuk","sameAs":["analytics"]}]}},"_links":{"self":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts\/136525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/comments?post=136525"}],"version-history":[{"count":0,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/posts\/136525\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/media\/30516"}],"wp:attachment":[{"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/media?parent=136525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/categories?post=136525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/tags?post=136525"},{"taxonomy":"search-category","embeddable":true,"href":"https:\/\/wfh.org\/es\/wp-json\/wp\/v2\/search-category?post=136525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}